Psyched: MindMed To Begin Mescaline Trials and Deepak Chopra Partnership, Seelos And Cybin Advance Clinical Research

MindMed’s News Spree: Mescaline Trials, Chopra Foundation Partnership and LSD Research

MindMed (NASDAQ: MNMD) (NEO: MMED) released a series of new announcements following the company’s Q1 earnings report.

The company reported Thursday that it had obtained authorization from one of the local Swiss ethics committees to conduct its first clinical trial on mescaline.

The research is scheduled to begin in May at the University Hospital Basel Liechti Lab in Basel, Switzerland.

The study will examine the effects of various doses of mescaline and “the role of the serotonin 5-HT2A receptor in a mescaline-induced altered state of consciousness.”

MindMed noted that the importance of this study lies in the fact that valid studies on the effects of different doses of mescaline, including placebo, are few and far between. The company will also gather data from the trial and create a foundation for future clinical trials on the medical potential of mescaline.

“This study will, we believe, provide the first modern research data on mescaline regarding dosing and mechanism of action in humans,” said Dr. Matthias Liechti, Ph.D., M.D. and professor of clinical pharmacology and internal medicine at the University of Basel.

The company also announced it had signed a new letter of intent to partner with The Chopra Foundation, a nonprofit led by spiritual author Deepak Chopra, with the goal of raising public awareness about the use of psychedelic medicines.

The two organizations are planning a research partnership in which they will ...

Full story available on Benzinga.com

Read More